Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Johnson & Johnson
(NY:
JNJ
)
146.82
UNCHANGED
Streaming Delayed Price
Updated: 7:00 PM EDT, Apr 25, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Johnson & Johnson
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Investor patience tested as pharmaceutical stocks take a tumble
November 01, 2023
The healthcare sector faces a selloff as pharmaceutical giants report lackluster earnings; even Amgen's strong results failed to prevent selling in the sector
Via
MarketBeat
J&J stock down as business unit mulls talc-related bankruptcy
October 31, 2023
Johnson & Johnson stock fell in the past week as talc-related lawsuits weigh on a subsidiary, which is mulling bankruptcy to mitigate payouts and settlements.
Via
MarketBeat
Topics
Bankruptcy
Lawsuit
Exposures
Financial
Legal
Are These 3 Dividend Aristocrats Undervalued Hidden Gems?
October 25, 2023
Dividend aristocrats Caterpillar, NextEra, and Clorox have shown resilience in challenging times. These may offer opportunities as they are trading off highs.
Via
MarketBeat
Exposures
COVID-19
Johnson & Johnson Announces Departure of Ashley McEvoy, Tim Schmid Named Executive Vice President, Worldwide Chairman of MedTech
October 23, 2023
From
Johnson & Johnson
Via
Business Wire
Johnson & Johnson (NYSE: JNJ) is One of Monday Morning’s Most Active Stocks
August 21, 2023
Via
Investor Brand Network
The Value Deepens for Medtech Stocks: Reversal Imminent
October 23, 2023
MedTech stocks are performing well and supported by pent-up demand, yet share prices are trading at significant and often historical lows.
Via
MarketBeat
Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2023
October 19, 2023
From
Johnson & Johnson
Via
Business Wire
Oversold and Overextended, Abbott Laboratories is a Great Buy
October 18, 2023
Abbott Laboratories rises on solid results and guidance; the value and dividend are at the best levels in years, and the sell-side is buying.
Via
MarketBeat
Exposures
COVID-19
Johnson & Johnson Reports Q3 2023 Results
October 17, 2023
From
Johnson & Johnson
Via
Business Wire
Steroids Market Is Set to Fly High in Years to Come : Pfizer, Johnson & Johnson, Bayer
October 10, 2023
Stay up to date with Steroids Market research offered by HTF MI. Check how key trends and emerging drivers are shaping this industry growth.
Via
SBWire
3 Undervalued Healthcare Stocks to Watch as Sector Struggles
October 06, 2023
As the healthcare sector slumps, several major stocks, including Zimmer Biomet, Moderna, and Illumina, appear undervalued in contrast to their intrinsic worth.
Via
MarketBeat
3 Blue Chip Safe Havens to Shield Your Portfolio
September 25, 2023
As the market experiences heightened volatility and uncertainty, it's worth exploring defensive stocks like JNJ, PG, and VZ for stability amid the uncertainty.
Via
MarketBeat
Topics
ETFs
Economy
Exposures
Economy
Interest Rates
3 Reasons SharkNinja Is Swimming Toward New Highs
September 22, 2023
Shares of SharkNinja, Inc. are up more than 50% since August 4th — and becoming a popular momentum bet amongst retail traders.
Via
MarketBeat
Flee to Healthcare Stocks if Recession Rears its Head?
September 20, 2023
In uncertain economic conditions, healthcare stocks can be a refuge due to steady demand and favorable inflation conditions. Many also offer dividends.
Via
MarketBeat
Topics
Economy
Exposures
Economy
Interest Rates
The Breakthrough Therapy Aiming To Solve The World’s Mental Health Crisis
September 19, 2023
EQNX::TICKER_START (NYSE:JNJ),(NYSE:ABBV),(NASDAQ:ATAI),(NASDAQ:CMPS),(NASDAQ:MNMD) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Economy
Exposures
Economy
Product Safety
Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results
September 18, 2023
From
Johnson & Johnson
Via
Business Wire
Johnson & Johnson Marks New Era as Global Healthcare Company With Updated Visual Identity
September 14, 2023
From
Johnson & Johnson
Via
Business Wire
Dividend Growth Rates and How to Calculate Them
September 08, 2023
Via
MarketBeat
7 Best Blue Chip Stocks to Buy Now
September 08, 2023
Blue-chip stocks are the stocks of well-known, high-quality industry leaders. Learn more about our top picks for the best blue chip stocks to buy now.
Via
MarketBeat
Global Dry Eye Syndrome Treatment Market Expected to Reach $11.26 Billion By 2030
September 08, 2023
EQNX::TICKER_START (NASDAQ:OKYO),(NYSE:ALC),(NYSE:BLCO),(NYSE:JNJ),(OTCQX:RHHBY) EQNX::TICKER_END
Via
FinancialNewsMedia
Exposures
COVID-19
3 Stocks Awaiting Winter Winds of Opportunity
September 07, 2023
The change in seasons favors specific stocks like JNJ, GOOS, and MTN, which exhibit growth patterns tied to seasonal changes.
Via
MarketBeat
J&J Spinoff Kenvue is the New Dividend Aristocrat on the Block
September 07, 2023
Newly public company Kenvue, a spinoff from Johnson & Johnson, joins the ranks of dividend aristocrats, offering a 3.57% yield, and 2022 sales of $15 billion.
Via
MarketBeat
Topics
ETFs
How Much Pain Will Lower Medicare Prices Cause for Pharma Stocks?
September 01, 2023
Pharmaceutical stocks are holding steady as Medicare price negotiations approach, but industry diversification and innovation support future growth prospects.
Via
MarketBeat
Topics
Economy
Exposures
Interest Rates
Johnson & Johnson Announces Updated Financials and 2023 Guidance Following Completion of the Kenvue Separation
August 30, 2023
From
Johnson & Johnson
Via
Business Wire
3 High Short Interest Stocks that Investors are Getting Wrong
August 25, 2023
Heavy short interest can be a sell signal, but these three stocks have bullish stories that make them attractive investments despite heavy short interest
Via
MarketBeat
Exposures
Fossil Fuels
Disney's Big Breakup? Wall Street, Iger Ponder A Magical Split
August 23, 2023
Disney is facing decisions about a potential split, with a focus on core businesses like streaming, parks, and film studios. CEO Bob Iger remains noncommittal.
Via
MarketBeat
Topics
Earnings
Exposures
Financial
Johnson & Johnson Announces Final Results of Exchange Offer and Finalizes Separation of Kenvue Inc.
August 23, 2023
From
Johnson & Johnson
Via
Business Wire
Johnson & Johnson to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
August 22, 2023
From
Johnson & Johnson
Via
Business Wire
Johnson & Johnson Announces Preliminary Results of Kenvue Inc. Exchange Offer
August 21, 2023
From
Johnson & Johnson
Via
Business Wire
Antiepileptic Drugs Market to Witness Massive Growth by 2028 : Johnson & Johnson, Sumitomo Pharma, Sanofi
August 17, 2023
Stay up to date with Antiepileptic Drugs Market research offered by HTF MI. Check how key trends and emerging drivers are shaping this industry growth.
Via
SBWire
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.